Semi-Quantitative Evaluation of Taste Distortion Caused By Radioiodine Therapy in Patients with Thyroid Cancer

Program: Abstracts - Orals, Poster Previews, and Posters
Session: SAT 270-310-Thyroid Neoplasia (posters)
Clinical/Translational
Saturday, April 2, 2016: 1:15 PM-3:15 PM
Exhibit/Poster Hall (BCEC)

Poster Board SAT 305
Takao Ando*, Aya Nozaki, Ai Haraguchi, Ayako Ito, Ikuko Ueki Sagara, Ichiro Horie, Misa Imaizumi, Toshiro Usa and Atsushi Kawakami
Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Backgrounds: Taste distortion is one of the major acute adverse effects of radioiodine therapy to thyroid cancer. However, the details of taste distortion and its relation to radioiodine accumulation to the salivary gland are not known.

Aim: To examine taste distortion after radioiodine therapy and to study the association between taste distortion and radioiodine accumulation in the salivary gland.

Methods: Fifty-three patients were studied with their tastes before and 5 weeks after radioiodine therapy to thyroid cancer from December 2011 to March 2015 in our Institute (average ages were 60.2 ± 14.3 years old with 70% of female). Four senses of taste, sweet, salt, sour, and bitter, were evaluated by using the filter-paper disc method which gives taste score from 1 to 9; higher the score, worse the taste. Radioiodine accumulation in the salivary gland was graded from 0 (no visible uptake) to III (higher than hepatic uptake).

Results: We found significant taste distortion in senses of sweet (from 3.6 ±1.7 to 4.2 ±1.9, p<0.05), salt (from 3.4 ±1.8 to 4.4 ±2.0, p<0.0005), bitter (from 3.6 ± 1.6 to 4.1 ±1.4, p<0.01), but not in that of sour (from 4.7 ±1.7 to 4.9 ±1.5, p>0.05). Radioiodine uptake in the salivary gland was graded as I in 5, II in 24, and III in 24 patients. There were no patients showed grade 0 uptake. Patients with high salivary radioiodine uptake developed sweet taste distortion more frequently than those with low (the differences in the taste scores before and after radioiodine therapy were -1.0, 0.8, and 0.9 in grade I, II, and III, respectively. p<0.05 in grade I vs. II and p<0.05 in grade I vs. III). We were not able to find such relations in other tastes. There was no association of taste distortion with age, sex, body weight, TSH on radioiodine administration, frequency of radioiodine therapy, or dose of radioiodine.

Conclusions: We showed that patients who underwent radioiodine therapy to thyroid cancer developed taste distortion in sense of sweet, salt, and bitter. Radioiodine uptake in the salivary gland was associated with sweet taste distortion.

Nothing to Disclose: TA, AN, AH, AI, IUS, IH, MI, TU, AK

*Please take note of The Endocrine Society's News Embargo Policy at https://www.endocrine.org/news-room/endo-annual-meeting/pr-resources-for-endo